Chromosomal Alteration Patterns in PitNETs: Massive Losses in Aggressive Tumors

Overview

Journal Endocr Relat Cancer

Specialties Endocrinology
Oncology

Date 2024 Oct 23

PMID 39441837

Authors

Maaia Margo Jentus

Leontine Bakker

Marco Verstegen

Iris Pelsma

Tom van Wezel

Dina Ruano

Ellen Kapiteijn

Stijn Crobach

Nienke Biermasz

Hans Morreau

Affiliations

Soon will be listed here.

Abstract

The molecular biology of pituitary neuroendocrine tumors (PitNETs) revealed few recurrent mutations and extensive chromosomal alterations, with the latter being the driving force in a subset of these lesions. Addressing the need for an easily applicable diagnostic tool, we conducted a retrospective study of 61 PitNETs operated at a tertiary care center. All cases were subtyped according to the 2022 WHO Classification of Endocrine Tumors. A genome-wide next-generation sequencing panel targeting 1500 single nucleotide polymorphisms (SNPs) was used to classify chromosomal imbalances, loss of heterozygosity, and copy number variations in DNA from formalin-fixed paraffin-embedded tissues. We identified four distinct chromosomal patterns, with varying distribution among different tumor lineages. Forty-two of 61 (69%) PitNETs showed chromosomal alterations. Gonadotroph PitNETs showed mostly quiet genomes. The majority of lactotroph PitNETs (19/20, 95%) were altered, exhibiting a gained genome and a remarkably low recurrence rate. Nine of ten (90%) corticotroph PitNETs harbored chromosomal alterations, of which two aggressive corticotroph tumors and one metastatic corticotroph PitNET showed massive chromosomal losses, leading to near-haploid/near-homozygous genomes. The comparison of the molecular profile of primary and recurrent PitNETs of five patients showed no significant accumulation of alterations over time. A simple genome-wide 1500-SNP test can be used in the identification of outspoken aggressive subsets of PitNETs by the occurrence of a near-haploid/near-homozygous genome. Furthermore, the presence of neoplastic tissue in the resected material can be potentially confirmed for non-gonadotroph PitNETs under suboptimal histological assessment conditions.

References

Zheng S, Cherniack A, Dewal N, Moffitt R, Danilova L, Murray B . Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016; 29(5):723-736. PMC: 4864952. DOI: 10.1016/j.ccell.2016.04.002. View

Gomez-Hernandez K, Ezzat S, Asa S, Mete O . Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg. 2015; 31 Suppl 1:4-17. DOI: 10.5146/tjpath.2015.01311. View

Mete O, Ezzat S, Asa S . Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. 2012; 49(2):R69-78. DOI: 10.1530/JME-12-0113. View

Villa C, Baussart B, Assie G, Raverot G, Roncaroli F . The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocr Relat Cancer. 2023; 30(8). DOI: 10.1530/ERC-23-0021. View

Sapkota S, Horiguchi K, Tosaka M, Yamada S, Yamada M . Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2016; 102(2):566-575. DOI: 10.1210/jc.2016-2261. View

Heaphy C, Bi W, Coy S, Davis C, Gallia G, Santagata S . Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020; 33(8):1475-1481. PMC: 8867890. DOI: 10.1038/s41379-020-0523-2. View

Corver W, van Wezel T, Molenaar K, Schrumpf M, van den Akker B, van Eijk R . Near-haploidization significantly associates with oncocytic adrenocortical, thyroid, and parathyroid tumors but not with mitochondrial DNA mutations. Genes Chromosomes Cancer. 2014; 53(10):833-44. DOI: 10.1002/gcc.22194. View

Asa S, Ezzat S . Pituitary carcinoma: reclassification and implications in the NET schema. Endocr Oncol. 2023; 2(1):R14-R23. PMC: 10259303. DOI: 10.1530/EO-22-0041. View

Trouillas J, Jaffrain-Rea M, Vasiljevic A, Raverot G, Roncaroli F, Villa C . How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020; 12(2). PMC: 7072139. DOI: 10.3390/cancers12020514. View

10.

Fountas A, Lavrentaki A, Subramanian A, Toulis K, Nirantharakumar K, Karavitaki N . Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2018; . DOI: 10.1210/jc.2018-01956. View

11.

Delgrange E, Vasiljevic A, Wierinckx A, Francois P, Jouanneau E, Raverot G . Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol. 2015; 172(6):791-801. DOI: 10.1530/EJE-14-0990. View

12.

Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G . A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126(1):123-35. DOI: 10.1007/s00401-013-1084-y. View

13.

Hung Y, Dong F, Dubuc A, Dal Cin P, Bueno R, Chirieac L . Molecular characterization of localized pleural mesothelioma. Mod Pathol. 2019; 33(2):271-280. PMC: 7359734. DOI: 10.1038/s41379-019-0330-9. View

14.

Uzilov A, Taik P, Cheesman K, Javanmard P, Ying K, Roehnelt A . USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors. J Clin Endocrinol Metab. 2020; 106(3):826-842. DOI: 10.1210/clinem/dgaa853. View

15.

Manojlovic-Gacic E, Engstrom B, Casar-Borota O . Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary. 2017; 21(2):119-129. PMC: 5849671. DOI: 10.1007/s11102-017-0855-1. View

16.

Gopal R, Kubler K, Calvo S, Polak P, Livitz D, Rosebrock D . Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell. 2018; 34(2):242-255.e5. PMC: 6121811. DOI: 10.1016/j.ccell.2018.06.013. View

17.

de Koster E, Corver W, de Geus-Oei L, Oyen W, Ruano D, Schepers A . A clinically applicable molecular classification of oncocytic cell thyroid nodules. Endocr Relat Cancer. 2023; 30(9). PMC: 10448578. DOI: 10.1530/ERC-23-0047. View

18.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V . Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell. 2018; 34(2):256-270.e5. PMC: 6247912. DOI: 10.1016/j.ccell.2018.07.002. View

19.

Asa S, Mete O, Cusimano M, McCutcheon I, Perry A, Yamada S . Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol. 2021; 34(9):1634-1650. DOI: 10.1038/s41379-021-00820-y. View

20.

Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson M, Septier A . Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2019; 37(1):123-134.e5. DOI: 10.1016/j.ccell.2019.11.002. View